Ohyama Dermatology Clinic

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Psoriasis4 trials

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Completed3 trials
• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Takeda3 trials
• Verrica Pharmaceuticals Inc.2 trials
• DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company1 trial

Running trials

• Recruiting

  Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)

  NCT07637734· Phase 3· Verrica Pharmaceuticals Inc.· Source

  Contact: Project Manager

• Recruiting

  Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

  NCT07457918· Phase 3· Verrica Pharmaceuticals Inc.· Source

  Contact: Project Manager

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Completed

  A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06602219· Phase 2· DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source